021. HIV State of the Art
Thursday, October 5, 2017: 8:30 AM-10:00 AM
Room: 06CF

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • identify the most appropriate antiretroviral therapy regimens for initial treatment and subsequent therapies for management of HIV infection in adults
  • evaluate drug costs and their potential impact on HIV treatment
  • review the approaches to effectively responding to the substance and mental health needs of patients with HIV

Target Audience: Fellows, HIV clinicians, HIV specialists, Members-in-training, Pharmacists, Public health practitioners

Tracks: Pediatric ID, HIV-STD-TB, Adult ID

Moderators:  Eric Daar, MD, Harbor-UCLA Medical Center and Monica Gandhi, MD, MPH, Division of HIV, Infectious Diseases and Global Medicine, UCSF

8:30 AM
What to Start and When to Switch
Joseph Eron Jr., MD

8:55 AM
9:20 AM
Substance Use and HIV: Vicious Twins
Gregory Lucas, MD, PhD

9:45 AM

CME Credits: Maximum of 1.50 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-17-233-L02-P


E. Daar, Bristol Myers Squibb: Consultant , Consulting fee
Gilead: Consultant and Grant Investigator , Consulting fee and Research grant
Janssen: Consultant , Consulting fee
Merck: Consultant and Grant Investigator , Consulting fee and Research grant
Teva: Consultant , Consulting fee
Theratechnologies: Consultant , Consulting fee
ViiV: Consultant and Grant Investigator , Consulting fee and Grant recipient

M. Gandhi, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.